Navigation Links
JCI early table of contents for April 15, 2013
Date:4/15/2013

Researchers untangle molecular pathology of giant axonal neuropathy

Giant axonal neuropathy (GAN) is a rare genetic disorder that causes central and peripheral nervous system dysfunction. GAN is known to be caused by mutations in the gigaxonin gene and is characterized by tangling and aggregation of neural projections, but the mechanistic link between the genetic mutation and the effects on neurons is unclear. In this issue of the Journal of Clinical Investigation, Robert Goldman and colleagues at Northwestern University uncover how mutations in gigaxonin contribute to neural aggregation.They demonstrated that gigaxonin regulates the degradation of neurofilament proteins, which help to guide outgrowth and morphology of neural projections. Loss of gigaxonin in either GAN patient cells or transgenic mice increased levels of neurofilament proteins, causing tangling and aggregation of neural projections. Importantly, expression of gigaxonin allowed for clearance of neurofilament proteins in neurons. These findings demonstrate that mutations in gigaxonin cause accumulation of neurofilament proteins and shed light on the molecular pathology of GAN.

TITLE: Giant axonal neuropathy-assoicated gigaxonin mutations impair intermediate filament protein degradation

AUTHOR CONTACT:
Robert Goldman
Northwestern University Medical School, Chicago, IL, USA
Phone: 312-503-4215; E-mail: r-goldman@northwestern.edu

View this article at: http://www.jci.org/articles/view/66387?key=fbb27aa987681b6b9d6a


Resistance is futile: researchers identify gene that mediates cisplatin resistance in ovarian cancer

Platinum compounds, such as cisplatin and carboplatin, induce DNA cross-linking, prohibiting DNA synthesis and repair in rapidly dividing cells. They are first line therapeutics in the treatment of many solid tumors, but cancer cells frequently develop resistance to these drugs. Mechanisms of resistance typically include reduced platinum uptake and increased platinum export. In this issue of the Journal of Clinical Investigation, Anil Sood and colleagues at M.D. Anderson Cancer Center identified a cellular membrane protein, ATP11B, that mediates cisplatin resistance in ovarian cancer cells. They found that ATP11B expression was correlated with higher tumor grade in human ovarian cancer samples and with cisplatin-resistance in human ovarian cancer cell lines. Further, loss of ATP11B restored the sensitivity of ovarian cancer cell lines to cisplatin and reduced ovarian tumor growth in mice. These findings suggest that ATP11B could serve as a therapeutic target to overcome cisplatin resistance.

TITLE: ATP11B mediates platinum resistance in ovarian cancer

AUTHOR CONTACT:
Anil Sood
M. D. Anderson Cancer Center, Houston, TX, USA
Phone: 713-745-5266; Fax: 713-792-7586; E-mail: asood@mdanderson.org

View this article at: http://www.jci.org/articles/view/65425?key=1b568a84b2ed6f3104ee


ALSO IN THIS ISSUE

TITLE: RNA binding protein PCBP2 modulates glioma growth by regulating FHL3

AUTHOR CONTACT:
Xiaozhong Peng
Institute of Basic Medical Sciences & School of Basic Medicine,Chinese Acad, Beijing, CHN
Phone: 0086-010-65296434; E-mail: peng_xiaozhong@163.com

View this article at: http://www.jci.org/articles/view/61820?key=1198455a7ca0e03c53ba

TITLE: IL-33 dependent induction of allergic lung inflammation by FcγRIII signaling

AUTHOR CONTACT:
Anne Sperling
University of Chicago, Chicago, IL, USA
Phone: 773-834-1211; Fax: 773-702-4736; E-mail: asperlin@uchicago.edu

View this article at: http://www.jci.org/articles/view/63802?key=032761d160603a5e9093

TITLE: WNT signaling underlies the pathogenesis of neuropathic pain in rats

AUTHOR CONTACT:
Xue-Jun Song
Parker University Research Institue, Dallas, , USA
Phone: 9734386932 EXT 7144

View this article at: http://www.jci.org/articles/view/65364?key=b983094cb01c7ee80e34

TITLE: Defective telomere elongation and hematopoiesis from telomerase-mutant aplastic anemia iPSCs

AUTHOR CONTACT:
Cynthia E. Dunbar
NIH, National Heart, Lung and Blood Institute, Bethesda, MD, USA
Phone: 301 496 1434; Fax: 301-496-8396

View this article at: http://www.jci.org/articles/view/67146?key=2d1d1346d4a5bb96bb80

TITLE: Opposing chemokine gradients control human thymocyte migration in situ

AUTHOR CONTACT:
Ellen Robey
University of California, Berkeley, Berkeley, CA, USA
Phone: 510-642-8669

View this article at: http://www.jci.org/articles/view/67175?key=ea0f0474c71bcec79110

TITLE: GM-CSF contributes to aortic aneurysms resulting from SMAD3 deficiency

AUTHOR CONTACT:
Jiahong Xia
Union Hospital, Tongji Medical College, Huazhong University of Science and, Wuhan, CHN
Phone: 0086-13971038472; Fax: 0086-27- 85726337; E-mail: jiahong.xia@mail.hust.edu.cn

View this article at: http://www.jci.org/articles/view/67356?key=481605675f72b402a894

TITLE: Mer receptor tyrosine kinase is a novel therapeutic target in melanoma

AUTHOR CONTACT:
Douglas Graham
Univ of Colorado Anschutz Medical Campus, Aurora, CO, USA
Phone: 303-724-4006; Fax: 303-724-4015; E-mail: doug.graham@ucdenver.edu

View this article at: http://www.jci.org/articles/view/67816?key=c3beb1f407a41392c648


'/>"/>

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Related medicine news :

1. Fosamax Lawsuit Update: Bernstein Liebhard LLP Notes Nearly 2,600 Claims Alleging Fosamax Femur Fractures, Other Side Effects, Pending in New Jersey State Litigation
2. Living Well Assisted Living at Home Hosts Ongoing Support Group for Patients with Early Onset Alzheimer’s
3. Hospitals Work to Reduce Unnecessary Early Births
4. JCI early table of contents for April 8, 2013
5. Causes of migraines nearly impossible to determine
6. Nearly 30 Percent of Americans Have High Blood Pressure: CDC
7. Cartilage Gives Early Warning of Arthritis, Study Finds
8. JCI early table of contents for April 1, 2013
9. Early COPD diagnosis possible with nuclear medicine
10. Blood Test Might Spot Pancreatic Cancer Early, Study Finds
11. New metabolite-based diagnostic test could help detect pancreatic cancer early
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: